Clinical Trials Browser

Phase 2 × anetumab ravtansine × 90 days × Clear all

NCT03587311 2026-06-03

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Active not recruiting

Fallopian Tube Endometrioid Adenocarcinoma